Startup & Innovation Launchpad
Discover the Next Wave of Pharma & Healthcare Innovation

In collaboration with T-Hub
The Startup & Innovation Launchpad at the Global Pharma Partnering Summit 2026 brings emerging startups, breakthrough technologies and innovative healthcare solutions into the spotlight.
In collaboration with T-Hub, the Launchpad creates a platform for promising innovators to connect with pharmaceutical companies, investors, industry leaders and potential partners. It is designed to showcase emerging solutions, spark meaningful conversations and create opportunities for collaboration across the pharma and healthcare ecosystem.
Startups

Startup
D-NOME
D-NOME is a deep-tech biotechnology company advancing point-of-care molecular diagnostics through cell-free synthetic biology. Its proprietary platforms integrate synthetic biology, enzyme engineering and miniaturised devices to enable rapid, affordable, field-deployable pathogen detection across human health and One Health applications. By bringing molecular testing closer to where decisions are made, D-NOME aims to make pathogen intelligence accessible beyond conventional laboratory settings.

Startup
Helex
Helex is a biotechnology company with a mission to make curative genetic medicines a reality for patients with kidney diseases. Its proprietary non-viral lipid nanoparticle (LNP) delivery platform enables targeted delivery of therapeutic payloads to hard-to-reach kidney cells. The platform is complemented by Epic-Cure™, an AI-driven drug design platform that supports target identification to payload design, de-risking therapeutic development. Helex’s lead program is a potentially curative, single-dose gene editing therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a condition affecting over 12 million people worldwide with no cure available today. Helex has validated targeted delivery to the kidney across disease models and non-human primates, the closest models to humans.

Startup
Ferry Lifesciences
Ferry Lifesciences is building a modular, multiplexed, microfluidic point-of-care diagnostic platform. It consists of one handheld device, swappable reader modules and disposable cartridges, and it gives quantitative blood results from a fingerprick in minutes.
The core technical bets are two.
1. Modularity. A single control unit accepts hot-swappable optical and electrochemical reader modules. The costly electronics stay in the control unit, so each new biomarker panel ships as a cartridge and a low-cost module on the same device.
2. Aptamers over antibodies. Aptamers are thermally stable, chemically synthesized and cold-chain-independent. They can also bind small molecules that antibodies handle poorly. We use ML-driven in-silico simulation alongside wet lab screening to accelerate aptamer discovery, collapsing SELEX timelines by months. Our first ferritin campaign has already produced two high-affinity candidates.
The platform starts with the highest-volume tests and moves toward the hardest ones. Kidney panels (creatinine, urea, uric acid) and liver panels (ALT, AST, bilirubin) come first, since routine panels like these make up roughly 70% of diagnostic volume. Next is therapeutic drug monitoring for narrow-window drugs such as lithium, tacrolimus and valproate, where patients need frequent testing and no reliable point-of-care option exists today. Small molecules, proteins and nucleic acids follow. The first panel (haemoglobin, iron and ferritin on a single cartridge) is a deliberate low-risk wedge to establish clinical and regulatory trust. We have R²=0.98 validation on Hb and two Indian patent applications filed, covering cartridge assembly and method. We are targeting CDSCO clearance by end of Q2 2027, with an FDA pre-submission on a similar timeline. India is our proving ground for the first 1,000 devices, and the US is the primary market.

Startup
ACINTYO
India’s Pharmacy Operating System
Acintyo is a Hyderabad-based B2B pharmaceutical distribution and technology platform that gives pharma companies a governed, data-rich channel into India’s independent pharmacies — and gives those pharmacies the procurement power, working capital and intelligence of a national chain.
About Acintyo
Acintyo Local Oriented Customer Applications Pvt. Ltd. (est. 2018) is a B2B pharmaceutical distribution and technology company headquartered in Hyderabad. From our own licensed warehouses we supply independent retail pharmacies across Telangana (Hyderabad and 22 Tier-2 cities) and Andhra Pradesh (6 cities), through one platform that combines distribution, embedded retailer credit, private-label generics (Care Brands), pharmacy software and supply-chain intelligence.
India’s 8 lakh+ independent pharmacies dispense the majority of medicines in the country, yet for a pharma company they are the least visible, least governed part of the chain — and for the pharmacist they are the hardest place to compete with a national chain. Acintyo digitises that layer from both sides. We do not compete with the pharmacy; we equip it, and we give its suppliers a channel they can see, audit and plan against. The company has been profitable since 2023 and is now extending its model beyond the two Telugu states, starting with Maharashtra.
Proposed session — Focus areas 05 and 08
Title: The independent pharmacy, digitised: a governed B2B channel for pharma companies in Tier-2/3 India
Most of India’s medicines are dispensed by single-counter independent pharmacies, yet the distribution layer that feeds them is still manual, fragmented and opaque. Pharma companies see stockists, not counters; they discover secondary and tertiary sales weeks late; schemes leak; batches cannot be traced to the point of sale. The pharmacist, meanwhile, juggles thirty distributor relationships, borrows on a distributor’s tolerance and has no view of what is selling around him.
This session presents Acintyo’s operating model: one B2B platform that aggregates procurement across a catalogue of nearly 2 lakh SKUs; underwrites retailer credit from transaction data through NBFC partners; gives the pharmacy a chain-grade back office and a private-label product line; and gives pharma companies real-time secondary-sales dashboards, policy-driven institutional sales audit, batch-level traceability and AI demand forecasting from the counter upward. We will share what we learned building this across Telangana and Andhra Pradesh: why credit is the wedge that makes a channel sticky, why governed execution beats order aggregation, and what an auditable, timestamped sales record is worth to a manufacturer in the era of digital compliance.
Format: talk with Q&A; adaptable to 15–30 minutes or a panel seat. Best fit: Pharma Supply Chain & Market Access; AI and Digitalisation in Pharma; Startup & Innovation Launchpad.
Why Acintyo is strong in B2B
- Own distribution, not a marketplace. Licensed warehouses, tens of thousands of SKUs stocked in-house and a fully automated purchase-to-sale process. We hold the inventory, carry the licence and take responsibility for the order.
- Governed execution for suppliers. Real-time secondary-sales dashboards, institutional sales audit with policy-driven approvals, batch and QR-level traceability and SKU-wise demand forecasting — control that traditional stockists and B2B marketplaces do not provide.
- Embedded credit with zero NPAs. Retailer working capital underwritten from platform transaction data and disbursed through NBFC partners, off Acintyo’s balance sheet. Every order improves the underwriting; better underwriting unlocks more orders.
- Profitable and capital-efficient since 2023. A distribution business that has never burned cash — growth funded by unit economics, not subsidy.
- Asset-light city replication. A partner-warehouse playbook proven across Tier-2 Telangana and Andhra Pradesh, now being extended to new states.
- Compliance by design. Strictly B2B wholesale: Acintyo never transacts with the patient — the licensed pharmacy does. GST-aligned billing and batch traceability on every order.
How we empower retailers
- Chain-grade procurement. One order, one invoice and one credit line replace thirty-plus distributor relationships; aggregated volume pricing is passed through to the counter.
- Working capital that grows with the business. Credit limits set on the pharmacy’s own purchase history, not collateral — a good pharmacy is never stock-constrained by cash.
- Margin the retailer owns. Care Brands private-label generics and OTC give the independent pharmacy a product line with chain-like margins.
- A chain back-office for a single counter. Inventory, expiry tracking, GST billing and reorder intelligence on one platform, built for a Tier-2 proprietor.
- Intelligence, not just supply. What is moving in their catchment, fast and slow movers, stock planning guidance — the information a chain head office has, delivered to an independent owner.
What we bring to GPPS partners

Startup
Sense Health
Sense Health is pioneering next-generation AI-enabled prickless, cuffless and leadless wearables for integrated cardio-renal-metabolic monitoring (Blood glucose, Blood pressure, heart rate, respiration rate, blood oxygen saturation, and kidney parameters). Backed by 20+ patents, 4 trademarks, and clinical validation and trial in association with top Indian medical institutes including AIIMS, Osmania, our platform enables continuous, actionable health insights for better patient outcomes.

Startup
EXSURE Private Limited
EXSURE Private Limited is an exosome infrastructure company building the foundational technologies, products, and platforms required to accelerate extracellular vesicle research, manufacturing, and therapeutic translation. The company focuses on creating an integrated exosome ecosystem spanning isolation technologies, labeling tools, cell-derived exosomes, plant-derived exosomes, and exosome-mediated drug delivery systems.
At the core of EXSURE's platform is its ability to develop and translate exosome based technologies across multiple verticals, including oncology nanomedicine, research reagents, regenerative aesthetics, and bioactive exosome products. Its lead therapeutic program, ExoDS, is an exosome mediated doxorubicin delivery system designed for cancer therapy, while its product portfolio includes Exosure for exosome isolation, ExoTrace for exosome labeling, MSC-derived exosomes, and PlantExosure, a phytoexosome-based platform.
By building tools, workflows, source materials, analytical know how, and scalable exosome product pipelines, EXSURE aims to become a leading Indian infrastructure platform for the exosome industry enabling researchers, clinicians, biotech companies, and aesthetic innovators to access reliable, standardized, and translationally relevant exosome technologies.

Startup
Molecular Solutions Software Pvt. Ltd.
Artificial intelligence is redefining pharmaceutical research, and Molecular Solutions Software Pvt. Ltd. is helping research organizations harness its full potential. As a leading provider of AI-powered scientific software, the company enables pharmaceutical, biotechnology, CRO, CDMO, and academic institutions to accelerate every stage of drug discovery and development.
Its comprehensive portfolio spans AI-driven drug discovery, molecular modelling, ultra-large chemical space exploration, virtual screening, molecular dynamics, ADMET prediction, retrosynthesis, formulation development, PK/PD modelling, Electronic Laboratory Notebooks (ELN), and scientific data management. By partnering with globally recognized technology providers, Molecular Solutions empowers researchers to reduce development timelines, optimize laboratory workflows, lower experimental costs, and improve the probability of clinical success through predictive, data-driven research.
Positioned at the intersection of artificial intelligence, computational chemistry, and pharmaceutical innovation, the company is making advanced scientific technologies more accessible to researchers worldwide. As the life sciences industry embraces digital transformation, Molecular Solutions continues to enable faster, smarter, and more efficient research, supporting the development of next-generation therapies that can improve patient outcomes globally.

Startup
NeurOrbis
Empowering Innovation.
NeurOrbis is building AI-powered Technology Intelligence Platforms that transform manually curated data from patents, scientific literature, clinical trials, companies, market intelligence, and news into connected, actionable insights.
Our platforms provide a live, continuously evolving view of technology ecosystems, enabling R&D, IP, strategy, business development, and innovation teams to discover trends, assess opportunities, monitor competitors, and make faster, evidence-based decisions.
With AI-powered analysis, domain-specific curation, and collaborative workspaces, NeurOrbis brings research, intelligence, and decision-making together in one platform.

Startup
Kompasion Consultancy
Building leaders and transforming organisations.
Kompasion Consultancy partners with organisations and professionals to strengthen leadership capability, improve project execution, and accelerate business transformation through practical consulting, coaching, and AI-enabled solutions.
Founded by Dr. Nageshwar Rao Kompalli after more than two decades of senior corporate leadership across pharmaceuticals, healthcare, and global project management (most recently as Vice President and Executive Committee Member at Aragen Life Sciences, where he built three PMOs from the ground up), the consultancy brings hands-on industry experience rather than imported frameworks to its engagements.
Kompasion's programmes are built for Indian corporate and healthcare realities, grounded in behavioural science rather than motivational folklore, and backed by a 60-day mentoring model that continues long after the workshop ends. Its stated outcome is behavioural change, not knowledge transfer: supporting drug development, manufacturing, and regulatory project leadership across the pharmaceutical value chain, and helping CROs and CDMOs with client-facing project excellence and portfolio governance.
Core Practice Areas
- Executive Leadership Coaching
- Project Excellence & PMO Maturity
- AI-Enabled Transformation
- Emotional Intelligence & People-First Leadership
- Operational Excellence Consulting
- Organisational Performance Diagnostics
Investors

Investment professional
Paritosh Nayak
Vice President Investments · InvAscent

Investment professional
Swadeep Pillarisetti
Founding Partner and MD · Blue Ocean Venture Partners
Swadeep is Founding Partner & MD at Blue Ocean Venture Partners, a global investor group of serial entrepreneurs investing $Ms in and advising cutting edge early-stage deep-tech and AI startups across space, defence, robotics, smart materials & mfg, chips & semiconductors, EV, in India and abroad. He serves on the boards of many category-defining companies such as AutoNxt and KoinX, helping them raise millions of dollars and scale globally. He has represented India on global stages, including leading a third of the Indian startup delegation to S20, the G20’s startup summit on behalf of PanIIT. His academic background includes a B.Tech from IIT Madras and an MS in Bioengineering from Clemson.

Investment professional
Aditi Chilakapati
Aum Ventures
Aum Ventures (https://aumvc.com/) is an early-stage venture capital firm with a strategy to back high-calibre Indian founders, building breakthrough, innovation-driven, IP-led businesses with the ability to compete globally. The focus is deeptech and IP-led technologies. Within this broad range, Aum Ventures invests in sectors such as spacetech, semiconductors, defencetech, aerospace, energy, robotics, advanced manufacturing, artificial intelligence, bio/med-tech, and more, to build a portfolio of market-defining companies. Fund I was the First institutional VC investor in Skyroot Aerospace, whose Vikram-1 rocket successfully reached orbit on its first attempt on 18 July, 2026 making Skyroot the first Indian private company to do so. Fund I was the early backer of Azimuth AI, a company developing cutting-edge silicon chips for high- performance edge computing, whose first chip was unveiled by the Hon'ble Minister Mr. Ashwini Vaishnaw. Fund I made investments across Spacetech, Semiconductors, Artificial Intelligence (AI), and Defencetech.
What to Discover
Explore innovations across AI & Digital Health, Biotechnology, Drug Discovery, Clinical Research, Advanced Healthcare Technologies, Pharma Manufacturing, Data & Analytics and other emerging areas shaping the future of healthcare.
Whether you are a startup looking to showcase your solution, a pharmaceutical company seeking new technologies, or an investor exploring emerging opportunities, the Launchpad offers a space to discover what’s next and build meaningful industry connections.




